BBH vs IBB

BBHBVanEck Biotech ETF

IBBAiShares Biotechnology ETF

In short

BBH Biotech, distilled. BBH tracks an index of around 25 US-listed drug and diagnostics companies, so each name carries real weight instead of getting lost in a crowd. Running since 2011, at a fee below the typical biotech fund.

IBB Biotech's original index fund. Since 2001 IBB has packed the whole US biotech sector, roughly 250 names, into one line item for 0.44% a year, below what the typical biotech fund charges.

Stated mandate

BBH The fund seeks to track, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index. That index represents companies involved in developing, producing, marketing, and selling drugs based on genetic analysis and diagnostic equipment.

IBB The Fund seeks to track an index composed of U.S.-listed equities focused on the biotechnology sector.

Why people hold it

• BBH 0.35% a year, below the 0.50% typical for biotech funds and level with XBI.
• Around 25 holdings, so the leaders in the index actually move the fund rather than getting diluted across hundreds of tickers.
• Rules-based: it follows the MVIS US Listed Biotech 25 Index, no manager guessing which drug pipeline pans out.vaneck.com
• Trading since 2011, through several full biotech cycles, and it sits in the upper half of its biotech peer group.

• IBB A 2001 launch makes it one of the sector's originals, and it has grown into a multi-billion-dollar fund that trades actively.
• Roughly 250 stocks, so the whole US biotech bench comes along instead of a few marquee drugmakers.
• 0.44% a year, set by the prospectus and below the median fee in its biotech peer group.
• Sticks closely to the job in its prospectus: US-listed biotech equities, nothing exotic bolted on. That lands it in the upper half of its peer group.ishares.com

Worth knowing

• BBH Concentration cuts both ways: with roughly 25 names, one failed trial or patent cliff lands hard.
• One of the less-traded funds in the biotech aisle, so bid-ask spreads deserve attention. Limit orders are the usual fix.
• Not the cheapest seat in the category: IBBQ charges 0.19%.

• IBB Cheaper seats exist in the same aisle: IBBQ at 0.19%, BBP at 0.34%, XBI at 0.35%.
• One industry carries the whole fund. Trial readouts, FDA decisions and patent expiries drive it, with no other sector to cushion a rough patch.
• Distributions arrive quarterly, but biotech is a growth sector and payouts are a side effect, not the point.

Full BBH profile⁠

Full IBB profile⁠